Nephro Care India
- Market cap
- ₹ 137 Cr.
- P/E
- 47.5x
- P/B
- 2.49x
- 52-week range
- 50.05 – 156.35
- ROE
- 6%
- ROCE
- 8.7%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE SME
About
Nephro Care India Limited is an India-based company that operates as a healthcare provider. Its business is to provide a comprehensive 360-degree healthcare service to patients with kidney-related services. It operates only in non-invasive service. It offers a range of clinical and lifestyle solutions and services and renal insufficiency treatment for patients. Its treatment framework covers the entire range of lifestyle, physiological and spiritual aspects of wellness. It provides holistic care for renal failure patients, which includes consultation, treatment, and yoga. It offers nutritional support for diabetic kidney disease, hypertensive nephropathy, glomerular disease, renal transplant recipient, hemodialysis patient, IgA nephropathy, Lupus nephropathy, and ADPKD. It operates various clinics, such as Renal Transplant, Urology, and Vascular Surgery. It also offers other services, such as Pulmonary function test, EMG/NCV-testing, Uroflowmetry, EEG, Polysomnography, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Nephro Care India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)47.5 against a typical 48.9: cheaper than most peers (1st = cheapest).20th of 40
- Share price, 3 months+27.5% against a typical −10.9%.5th of 34
- Size₹ 136.8 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).25th of 36
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 7 Aug 2026 | Board Meeting Intimation | NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 07-Aug-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Other business. |
| 27 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 13 Feb 2026 | Board Meeting Intimation | NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 13-Feb-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2025 and Other business. |
| 12 Nov 2025 | Board Meeting Intimation | NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2025 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2025 and Other business. |
| 10 Jul 2025 | Board Meeting Intimation | NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 10-Jul-2025 to consider Other business. |
| 28 May 2025 | Board Meeting Intimation | NEPHRO CARE INDIA LIMITED has informed the Exchange about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2025 and Other business. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 17 | 23 | 27 | 29 |
| Expenses | 17 | 21 | 25 | 26 |
| Operating Profit | 1 | 2 | 2 | 4 |
| OPM % | 3.5% | 8.4% | 7.6% | 12.4% |
| Other Income | 0 | 0 | 1 | 0 |
| Interest | 0 | 0 | −0 | 0 |
| Depreciation | 1 | 1 | 2 | 1 |
| Profit before tax | −1 | 1 | 1 | 3 |
| Tax % | 0% | 25% | 23.1% | 38.2% |
| Net Profit | −1 | 0 | 1 | 2 |
| EPS in Rs | −0.39 | 0.25 | 0.61 | 0.98 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 118%
- 3 Years
- 73%
- TTM
- 93%
- 10 Years
- —
- 5 Years
- 106%
- 3 Years
- 12%
- TTM
- 17%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 13%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Nephro Care India | ₹ 80.25 | ₹ 137 Cr. | 47.5x | 2.5x | 6% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Pratim Sengupta
- Executive Chairman, Chief Executive Officer, Managing Director
- Tapas Saha
- Chief Financial Officer
- Arnab Majumder
- Chief Operating Officer
- Sougata Sengupta
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.